Login / Signup

Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial.

Monika GräserOleg GluzClaudia BiehlDaniel Ulbrich-GebauerMatthias ChristgenJenci PalattySherko KuemmelEva-Maria GrischkeDoris AugustinMichael BraunJochem PotenbergRachel WuerstleinKatja KraussClaudia SchumacherHelmut ForstbauerToralf ReimerAndrea StefekHans Holger FischerEnrico PelzChristine Zu EulenburgRonald Ernest KatesHua NiCornelia Kolberg-LiedtkeFriedrich FeuerhakeHans Heinrich KreipeUlrike NitzNadia Harbeck
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Distinct gene signatures were associated with pCR vs iDFS in HER2+/HR- EBC. The potential role of IR in preventing recurrence suggests that patients with up-regulated IR signatures could be candidates for de-escalation concepts in HER2+ EBC.
Keyphrases